B-Cell Non-Hodgkin Lymphoma Pipeline
LAS VEGAS, NV, UNITED STATES, February 4, 2025 /EINPresswire.com/ -- DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report
• In January 2025:- Hoffmann-La Roche:- This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients.
• In January 2025:- Bayer:- The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
• In January 2025:- Ryvu Therapeutics SA:- The study consists of 3 parts, to investigate MEN173 in combination with glofitamab in patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) or MEN1703 alone in patients who have exhausted all standard treatment options (group 2).
• DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
• The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
• Promising B-Cell Non-Hodgkin Lymphoma Therapies such as CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
Stay informed about the cutting-edge advancements in B-Cell Non-Hodgkin Lymphoma Treatments. Download for updates and be a part of the revolution in care @ B-Cell Non-Hodgkin Lymphoma Clinical Trials Assessment
B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile
• Valemetostat: Daiichi Sankyo
Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.
• MB-106: Mustang Bio
MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.
• CB-010: Caribou Biosciences
CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.
• LP-284: Lantern Pharma
LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern's RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.
Learn more about B-Cell Non-Hodgkin Lymphoma Drugs opportunities in our groundbreaking B-Cell Non-Hodgkin Lymphoma Research and development projects @ B-Cell Non-Hodgkin Lymphoma Unmet Needs
B-Cell Non-Hodgkin Lymphoma Companies
Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in B-Cell Non-Hodgkin Lymphoma Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr
Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report
• Coverage- Global
• B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
• B-Cell Non-Hodgkin Lymphoma Therapies- CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Non-Hodgkin Lymphoma Pipeline on our website @ B-Cell Non-Hodgkin Lymphoma Drugs and Companies- https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. B-Cell Non-Hodgkin Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Valemetostat: Daiichi Sankyo
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB-010: Caribou Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. B-Cell Non-Hodgkin Lymphoma Key Companies
21. B-Cell Non-Hodgkin Lymphoma Key Products
22. B-Cell Non-Hodgkin Lymphoma- Unmet Needs
23. B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
24. B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
25. B-Cell Non-Hodgkin Lymphoma Analyst Views
26. B-Cell Non-Hodgkin Lymphoma Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2025
Surgical Lasers Market - https://www.delveinsight.com/report-store/surgical-lasers-market
Intraocular Lens Market - https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Myeloproliferative Neoplasms Market - https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Skin Neoplasm Market - https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Healthcare Competitive Benchmarking - https://www.delveinsight.com/consulting/competitive-benchmarking-services
Microscopy Device Market - https://www.delveinsight.com/report-store/microscopy-device-market
Pacemakers Market - https://www.delveinsight.com/report-store/pacemakers-market
Urea Cycle Disorders Market - https://www.delveinsight.com/blog/urea-cycle-disorder-market
Novel Drug Delivery Devices Market - https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Nk Cell Therapy Market - https://www.delveinsight.com/infographics/nk-cell-therapy-market
Surgical Mask & Respirator Market - https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Lymphoedema Market - https://www.delveinsight.com/report-store/lymphoedema-market
Phototherapies For Psoriasis Market - https://www.delveinsight.com/report-store/phototherapy-devices-market
Sepsis Market - https://www.delveinsight.com/report-store/sepsis-market
Bone Growth Stimulator Market - https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody Drug Conjugate Market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Overactive Bladder Syndrome Market - https://www.delveinsight.com/report-store/underactive-bladder-market
Medical Marijuana Market - https://www.delveinsight.com/report-store/medical-marijuana-market
Lactose Intolerance Market - https://www.delveinsight.com/report-store/lactose-intolerance-market
Catheter Stabilization Devices Market - https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yash Bhardwaj
DelveInsight
+91 96502 13330
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
